Participants 23 140 5
phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma
Participants 143 443 6
A randomized, open-label, phase 2, multicenter clinical trial was conducted to evaluate the efficacy and safety of the addition of a recombinant human endostatin adenovirus (E10A) to cisplatin and paclitaxel in patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma.
Participants 444 728 6
Patients with locally advanced or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma not suitable for operation or radiotherapy were randomly assigned to receive E10A plus chemotherapy every 3 weeks for a maximum of six cycles or to receive chemotherapy only
Participants 730 798 6
One hundred and thirty-six eligible patients were randomly assigned.
Participants 1495 1654 4
E10A plus chemotherapy is a safe and effective therapeutic approach in patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma
